Neonatal outcomes following new reimbursement limitations on palivizumab in Italy.

Valeria BelleudiFrancesco TrottaLuigi PinnarelliMarina DavoliAntonio Addis

Published in: Archives of disease in childhood (2018)

Implementation of the new palivizumab reimbursement criteria was not associated with an increase in the RSV hospitalisation rate for children aged <2 years despite a significant reduction in the number of palivizumab prescriptions.

Keyphrases

respiratory syncytial virus
primary care
young adults
healthcare
respiratory tract